Proficio Capital Partners LLC lessened its position in shares of Pfizer, Inc. (NYSE:PFE) by 25.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,441 shares of the biopharmaceutical company’s stock after selling 7,789 shares during the quarter. Proficio Capital Partners LLC’s holdings in Pfizer were worth $739,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of PFE. Shine Investment Advisory Services Inc. purchased a new stake in shares of Pfizer in the second quarter worth about $102,000. D. Scott Neal Inc. boosted its stake in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of Pfizer in the first quarter worth about $121,000. Cascade Investment Advisors Inc. boosted its stake in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 2,200 shares during the last quarter. Finally, Perennial Advisors LLC boosted its stake in shares of Pfizer by 7.9% in the second quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 376 shares during the last quarter. Institutional investors and hedge funds own 69.34% of the company’s stock.
A number of analysts have recently commented on PFE shares. BMO Capital Markets upgraded Pfizer from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $33.00 to $37.00 in a research note on Wednesday, August 2nd. UBS AG reaffirmed a “buy” rating and issued a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $38.48.
Shares of Pfizer, Inc. (NYSE:PFE) opened at $35.37 on Monday. Pfizer, Inc. has a fifty-two week low of $30.51 and a fifty-two week high of $36.78. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The company has a market capitalization of $210,830.00, a P/E ratio of 14.15, a P/E/G ratio of 2.50 and a beta of 1.01.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter last year, the firm earned $0.61 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. research analysts forecast that Pfizer, Inc. will post 2.6 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.62%. Pfizer’s dividend payout ratio is presently 78.53%.
In related news, insider Sally Susman sold 38,230 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ian C. Read sold 197,168 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the completion of the transaction, the chief executive officer now owns 580,318 shares of the company’s stock, valued at $19,730,812. The disclosure for this sale can be found here. In the last ninety days, insiders sold 366,557 shares of company stock valued at $12,532,406. Insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.